a prescription for drugs during an out-patient visit and 12.04% reported having paid for the medicine. The total out-of-pocket expenditure in 2010 was USD$134,937. The difference in mean expenditure was statistically significant showing higher expenditure among women compared to men (p-value ϭ 0.0001). Statistical differences were also found across age groups (F-test ϭ16.46); the highest mean expenditure was observed in persons aged 60 years and older, followed by individuals in the age group 51-60 and 0-9 years old. Results from the logistic regression model show that younger men and women are more likely than those in the middle-aged groups to spend on medicine. People living in regions of very high socio-economic marginality spend more on drugs than their better off counterparts. Individuals registered at their family medical care unit are less likely to make expenditures for drugs than the non-registered. Illness increases the probability of drug spending by 0.065. CONCLUSIONS: The out-ofpocket drug expenditure among ambulatory care users varies according to social, economic and demographic factors at the individual and regional levels. OBJECTIVES:One of the most challenging problems for pharmaceutical policy is how to pay for very expensive new drugs for rare diseases, known as "Orphan drugs" (ODs). Aims of this work were to compare the expenditure and utilization of ODs among five European Union Countries (France, Germany, Italy, Spain, UK) and identify the ATC group with the major impact on Italian ODs expenditure and utilization. METHODS: European database from IMS and the AIFA internal database were consulted for the period 2009-2010 according to the ODs approved by European Medicines Agency. RESULTS: In all 5EU both utilization and expenditure increased in the year 2010 compared to 2009 ranging respectively around 13%-28% for the expenditure and around 7%-17% for the utilization. Italy is the third after Germany (917 Ml €) and France (828 Ml €) for the expenditure and the second after Germany (22 Ml standard units) for utilization. 80% of the ODs authorised by EMA is available in Italy, the remaining 20% is not accessible (marketing reasons). During 2010 Italian expenditure for ODs amounted to 5,5 Ml €, with an increase by 19% compared to 2009. According to the utilization, the value of ODs amounted to 20 Ml standard units, with an increase of 15% compared to 2009. "L" ATC code (antineoplastic) represents the highest expenditure (63% of total ODs) and utilization (60% of total ODs). Within "L" ATC group, Imatinib is the most used molecule (146 Ml € and 8,5 Ml standard units) with an average cost/patient/year of 38,500€ (assuming weight 70kg) ranging from 5,700€ (Anagrelide) and 44,500€ (Nilotinib). CONCLUSIONS: Results suggest that ODs expenditure and utilization is rapidly growing up, particularly for some ATC groups. The increase of ODs' utilization is a common challenge among EU countries in order to guarantee a balance between patient access and budget sustainability. PHP40
INTRODUCTION: Laparoscopic cholecystectomy is the most commonly performed general surgical procedure. During the COVID-19 pandemic, general recommendation worldwide is to postpone elective surgeries as far as possible to decrease the resource utilization and also aerosol-related transmission among hospital staff and patients. We conducted this study to see the burden of gallbladder disease, their management and outcomes of all patients who presented to our centre during first wave of COVID-19 pandemic. METHODS: We conducted a retrospective analysis of all patients who underwent laparoscopic cholecystectomy at the Hospital for Advanced Medicine and Surgery (HAMS) after the commencement of strict lockdown in the first wave of the COVID-19 pandemic. Ethical approval for the study was taken from Nepal Health Research Council. All the surgeries were performed as per HAMS interim policy for infection prevention and control during the COVID-19 pandemic. Data were extracted from the discharge sheet and outcomes in terms of duration of hospitalization, morbidity, mortality, and COVID -19 infection among patient and operating team staff after surgery were assessed. RESULTS: Out of 110 cases operated for gallbladder disease, 90 patients were included in the study with complete data. The most common presentations were dyspepsia (28) and biliary colic (22). Patients were managed with laparoscopic cholecystectomy (79), percutaneous cholecystostomy (4), laparoscopic subtotal cholecystectomy (5), open cholecystectomy (1). The median duration of hospitalization 22 hours. There was no COVID-19 transmission among staff and patients. CONCLUSIONS: Laparoscopic cholecystectomies are feasible during COVID-19 pandemic and safely performed following infection prevention guidelines. It can be still be performed in day case basis to decrease the bed occupancy and avoiding crowd in hospitals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.